Online inquiry

IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, Pseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ6549MR)

This product GTTS-WQ6549MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets TNF gene. The antibody can be applied in Uveitis research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000594.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 7124
UniProt ID P01375
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-TNF, D2E7(Cap 1, Pseudo-UTP, 30 nt-poly(A)) (GTTS-WQ6549MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ12242MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ2347MR IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA AME-133v
GTTS-WQ14990MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ13555MR IVTScrip™ mRNA-Anti-GPI-APs, PRX-302(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PRX-302
GTTS-WQ11054MR IVTScrip™ mRNA-Anti-EGFR&LGR5, MCLA-158(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MCLA-158
GTTS-WQ4764MR IVTScrip™ mRNA-Anti-TNFSF13B, BR3-Fc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA BR3-Fc
GTTS-WQ13925MR IVTScrip™ mRNA-Anti-INHBA, REGN2477(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA REGN2477
GTTS-WQ2212MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ALT-803
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW